Elan has MS drug filing accepted in US

Biogen Idec and Elan Corporation have announced that the US Food and Drug Administration (FDA) has formally accepted their Biologics License Application (BLA) for Multiple Sclerosis drug Antegren (natalizumab).

In June 2004, the FDA designated natalizumab for priority review and accelerated approval for the treatment of multiple sclerosis (MS). Acceptance of a filing indicates that the FDA has determined that the application is complete and permits a substantive review.